Antibody clues to Aids vaccine success

2012-04-05 19:32

Washington - The success of an Aids vaccine trial that in 2009 was shown to protect 31% of people studied may have been due to varying levels of antibody responses in the patients, researchers said on Thursday.

Different types of antibody responses were associated with who became infected and who did not, according to an analysis of the results published in the April 5 edition of the New England Journal of Medicine.

For instance, a type of antibody produced by the body to ward off infection, known as IgG, could attach itself to the surface of the HIV protein and appeared to help prevent infection in some people.

People received the vaccine and whose IgG antibodies were able to bind to this region, called V1V2, showed lower infection rates than the placebo group.

On the other hand, patients whose blood tests showed the highest levels of a different antibody, IgA, appeared to have less protection against HIV than people with lower levels, leading scientists to think it may have actually interfered with the vaccine and made it less effective.

"This analysis has produced some intriguing hints about what types of human immune responses a preventive HIV vaccine may need to induce," said National Institute of Allergy and Infectious Diseases (NIAID) director Anthony Fauci.

"With further exploration, this new knowledge may bring us a step closer to developing a broadly protective HIV vaccine," said Fauci, whose NIAID co-funded the research along with the US Army Medical Research and Materiel Command, and the Bill and Melinda Gates Foundation.

The latest analysis could help inform future vaccine trials by creating more effective vaccines and possibly figuring out how to make variations that work best in different patients.

"Different HIV vaccines may protect against HIV in different ways," said co-author Nelson Michael, military HIV research programme director at Walter Reed Army Institute of Research.

"More research is needed to fully understand these results, and to determine if they can be generalised to other types of HIV vaccines or similar vaccines tested against other regional types of HIV or via different routes of exposure."

The trial data, based on results from 16 395 HIV-negative volunteers in Thailand and first published in 2009, was viewed as a pioneering achievement even though it provided only a partial shield against HIV.

A vaccine would have to offer 50% protection in order to be offered to the public.

Aids has claimed more than 25 million lives since 1981 and left more than 30 million people infected.

Read more on:    hiv aids  |  research

Join the conversation! encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

linking and moving

2015-04-22 07:36 publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24


Book flights

Compare, Book, Fly

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.